Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States

Auerbach, Jeremy M.; Moghalu, Odinachi; Das, Rupam; Horns, Joshua J.; Campbell, Alexander J. A.; Hotaling, James M.; Pastuszak, Alexander W.

doi:10.1038/s41443-021-00471-2

Cited by 6 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Testosterone deficiency (TD) is a common condition affecting men with increasing prevalence as they age [ 1 , 2 ]. Patients with TD present with a varied constellation of signs and symptoms, including muscle wasting, fatigue, osteoporosis, oligospermia, and obesity.…”

Section: Introductionmentioning

confidence: 99%

Trends in testosterone prescription during the release of society guidelines

et al. 2023

View full text Add to dashboard Cite

The American Urological Association and Endocrine Society published guidelines for the management of testosterone deficiency in 2018. Testosterone prescription patterns have varied widely recently, owing to increased public interest and emerging data on the safety of testosterone therapy. The effect of guideline publication on testosterone prescribing is unknown. Thus, we aimed to assess testosterone prescription trends using Medicare prescriber data. Specialties with over 100 testosterone prescribers from 2016–2019 were analyzed. Nine specialties were included (in order of descending prescription frequency): family practice, internal medicine, urology, endocrinology, nurse practitioners, physician assistants, general practice, infectious disease, and emergency medicine. The number of prescribers grew by a mean of 8.8% annually. There was a significant increase in average claims per provider from 2016 to 2019 (26.4 to 28.7, p < 0.0001), with the steepest increase occurring between 2017 and 2018 when the guidelines were released (27.2 to 28.1, p = 0.015). The largest increase in claims per provider was among urologists. Advanced practice providers comprised 7.5% of Medicare testosterone claims in 2016 and 11.6% in 2019. While no causation can be established, these results suggest that professional society guidelines are associated with increasing numbers of testosterone claims per provider, especially among urologists. The changing demographics of prescribers justifies targeted education and further research.

show abstract

Section: Introductionmentioning

confidence: 99%

Trends in testosterone prescription during the release of society guidelines

et al. 2023

View full text Add to dashboard Cite

show abstract

Dietary trends and the decline in male reproductive health

Whittaker

2023

Hormones

View full text Add to dashboard Cite

Newer formulations of oral testosterone undecanoate: development and liver side effects

Goldstein,

Chidambaram,

Dobs

et al. 2024

Sexual Medicine Reviews

View full text Add to dashboard Cite

Introduction Testosterone deficiency is a clinical disorder due to either failure of the testes to produce testosterone or failure of the hypothalamus or pituitary to produce sufficient gonadotropins. Previous formulations of oral testosterone therapy, particularly methyltestosterone, have been associated with adverse liver effects. Many different routes of testosterone delivery have been developed, each with their own administrative benefits and challenges. Newer formulations of oral testosterone undecanoate (TU) provide a convenient administration option, although their use has been limited by hepatotoxicity concerns based on older methyltestosterone data, and prescribing physicians may still be concerned about adverse liver effects. Objectives In this review, we discuss the history of oral testosterone development, clarify the mechanism of action of oral TU, and describe the relevant liver safety findings. Methods Relevant literature was allocated to present a review on the history of oral TU development and the mechanism of action of oral TU. We pooled data from individual studies of oral TU products to present a safety summary. Results Overall, safety results from studies of the newer formulations of oral TU showed that increased liver function test values are not generally associated with oral TU formulations and that no clinically significant liver toxicities were noted in clinical trials of oral TU. Conclusion Continued research into the safety of oral TU will contribute to a better understanding of the potential risks in patients receiving this therapy, an outcome that highlights the importance of providing patient education and reassurance regarding oral TU safety.

show abstract

Evaluating incidence, prevalence, and treatment trends in adult men with hypogonadism in the United States

Cited by 6 publications

References 12 publications

Trends in testosterone prescription during the release of society guidelines

Trends in testosterone prescription during the release of society guidelines

Dietary trends and the decline in male reproductive health

Newer formulations of oral testosterone undecanoate: development and liver side effects

Contact Info

Product

Resources

About